<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724412</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-07-15</org_study_id>
    <nct_id>NCT00724412</nct_id>
  </id_info>
  <brief_title>Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of two Dry Eye products
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Break-up time</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optive</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane</intervention_name>
    <description>Dry Eye relief eye drops</description>
    <arm_group_label>Systane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optive</intervention_name>
    <description>Dry Eye relief eye drops</description>
    <arm_group_label>Optive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Have a score of at least 2 (&quot;some of the time&quot;) on the subject-assessed Symptom
             Eligibility question; see Section 8.5.1.

          -  Have a sodium fluorescein corneal staining sum of ≥ 3 in either eye; see Section
             8.5.10.

          -  Have a best-corrected visual acuity of 0.6 log MAR or better in each eye as assessed
             using an ETDRS chart; see Section 8.5.7.

        Exclusion:

          -  Have a history or current evidence of the following: epithelial herpes simplex
             keratitis (dendrictic keratitisis); vaccinia, active or recent varicella viral disease
             of the cornea and/or conjunctiva; ocular rosacea; acute or chronic bacterial disease
             of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye;
             and/or fungal disease of the eye.

          -  Use of Restasis® (cyclosporine ophthalmic emulsion, 0.05%) within 30 days of Visit 1.

          -  Use of systemic medications that may contribute to dry eye if the dosing regimen has
             not been stable for at least 30 days prior to Visit

          -  Additionally, the dosing regimen must remain stable throughout the study period.
             Medications known to contribute to dry eye include, but are not limited to, cold and
             allergy treatments, tricyclic antidepressants, and hormone replacement therapies.

          -  Presence of ocular conditions such as active acute blepharitis, conjunctival
             infections, iritis, or any other ocular condition that may preclude the safe
             administration of the test article.

          -  Unwilling to discontinue contact lens wear at least 7 days prior to Visit 1 and during
             the study period.

          -  Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Corneal Staining</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

